相关实验视频
Updated: Jan 13, 2026

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
10.3K
儿科ALL中的Dexrazoxane心脏保护:一项历史对照队列研究
Li Liu1,2, Hongping Yang2, Yan Zhou3
1Institute of Advanced Biotechnology, Institute of Homeostatic Medicine, and School of Medicine, Southern University of Science and Technology, 518055, Shenzhen, China.
Cardio-oncology (London, England)
|January 9, 2026
概括
添加像德克斯拉佐这样的心脏保护策略显著减少了儿科急性淋巴细胞白血病 (ALL) 患者的心脏损伤,这些患者接受了环素治疗. 这种方法可以改善心脏健康,而不会增加不良事件.
科学领域:
- 儿科瘤学 儿科瘤学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 人环素对于治疗儿科急性淋巴细胞白血病 (ALL) 是至关重要的.
- 人环素可以引起显著的心脏毒性,影响长期的结果.
- 需要有效的心脏保护策略来减轻这种风险.
研究的目的:
- 评估心脏保护策略的有效性,以预防儿科ALL患者的antracycline诱导心脏毒性.
- 评估心脏保护剂在这个人群中的安全性.
主要方法:
- 在昆明儿童医院进行了一项雄心勃勃的队列研究.
- 患者被分为历史对照组 (没有德克斯拉松) 和前性对照组 (使用德克斯拉松).
- 心脏监测包括心电图,心声图和心脏生物标志物.
主要成果:
- 德克斯拉松组显示出显著较低的心电图和心声谱异常率 (P<0.01).
- 在德克斯拉松素组 (P<0.05) 中,观察到治疗后心脏中热素T水平的改善 (P<0.05).
- 与使用德克斯拉松相关的不良反应没有显著增加.
结论:
- 心脏保护策略,如德克斯拉佐,可以安全地纳入儿科ALL治疗方案.
- 这些策略有效地降低了环素诱导的心脏毒性,可能改善患者的治疗结果.
- 调查结果应在研究的非随机设计的背景下考虑.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
207
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
207
Pharmacokinetics in Pediatric Patients: Drug Distribution
251
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251
Pharmacokinetics in Pediatric Patients: Drug Metabolism
189
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
189
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
240
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
240
Drug Dosing: Infants and Children
248
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
248
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

